Procter & Gamble Health Share Price

Procter & Gamble Health Investment Rating

• Master Rating:

• Procter & Gamble Health has an operating revenue of Rs. 1,103.91 Cr. on a trailing 12-month basis. An annual revenue de-growth of -28% needs improvement, Pre-tax margin of 23% is great, ROE of 25% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 66 which is a FAIR score but needs to improve its earnings, a RS Rating of 27 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 94 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.